Regeneron stock gains analyst support after strong quarterly figures

Published on 09/20/2026 at 21:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock is backed by a Moderate Buy consensus and an average price target of USD 802.18 as of September 20, 2026. The company recently reported quarterly revenue up 16.7 percent year over year and EPS clearly above expectations.

Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen — Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron Pharmaceuticals stock (ISIN US75886F1075) is trading with solid analyst support, underpinned by recent quarterly figures that showed earnings per share of USD 14.29 against a USD 10.16 consensus estimate for the latest reported quarter, and revenue of USD 4.29 billion, up 16.7 percent year over year according to MarketBeat.

Analysts lift their view on Regeneron

As of September 20, 2026, Regeneron stock benefits from an upgrade to a strong-buy rating by Wall Street Zen, reflecting growing confidence in the earnings trajectory and product portfolio, according to MarketBeat.

Across the broader analyst community, Regeneron currently carries a consensus rating of Moderate Buy, with fourteen analysts rating the stock Buy and ten assigning Hold ratings, and the average price target stands at USD 802.18, offering a quantified benchmark for investors following the stock, according to MarketBeat.

Recent earnings beat consensus expectations

Regeneron’s most recently reported quarterly results, announced for its latest quarter on July 30, 2026, underscore the fundamental backdrop: the company delivered earnings per share of USD 14.29, surpassing the USD 10.16 consensus estimate by USD 4.13, which represents a positive earnings surprise of approximately 40.7 percent according to MarketBeat.

On the top line, quarterly revenue came in at USD 4.29 billion for the same period, above the USD 3.82 billion analyst consensus and marking a 16.7 percent increase compared with the prior-year quarter, providing a clear quantified signal that Regeneron is growing faster than its recent history according to MarketBeat.

Profitability and pipeline context

Beyond growth, profitability metrics help frame the investment case: in the latest quarter, Regeneron posted a net margin of 27.86 percent and a return on equity of 13.47 percent, illustrating that the company is converting its expanding revenue base into substantial bottom-line results according to MarketBeat.

The earnings momentum is reflected in full-year expectations as well: sell-side analysts currently forecast that Regeneron will post USD 44.25 in earnings per share for the current fiscal year, giving investors a concrete figure to compare against the latest quarterly run-rate and consensus price targets, according to MarketBeat.

Competition and risk around key products

Regeneron’s partnership with Sanofi on the blockbuster drug Dupixent remains a critical driver, but it also introduces long-term strategic questions as patent expiries move closer and the competitive landscape in immunology evolves, as highlighted in a sector piece discussing Sanofi’s plans to grow Dupixent sales and manage patent loss risk, according to Yahoo Finance.

For Regeneron stock, this context means that while current quarterly figures and analyst upgrades support the valuation, investors need to weigh future competition and potential pricing pressure in Dupixent and other key franchises against the company’s demonstrated ability to deliver double-digit revenue growth and high margins in its latest reported quarter, based on data from MarketBeat and Yahoo Finance.

Regeneron stock price and trading venue

On the market side, Regeneron stock is listed on Nasdaq in USD as its primary exchange venue, and price data as of the most recent completed trading day in mid-September 2026 show the shares trading in a range that investors compare with the consensus price target of USD 802.18 and the company’s recent earnings strength; this relationship between current price levels, analyst targets and double-digit revenue growth in the latest quarter is central for assessing upside and downside potential in the stock based on figures reported by MarketBeat.